Valvular & structural heart disease
Incidence, predictors, and clinical impact of hypoattenuating leaflet thickening following SAPIEN 3 Ultra RESILIA implantation
Authors' conclusion
The incidence of HALT for the S3UR was comparable with the already reported incidences for the previous-generation SAPIEN 3 THV.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 Ultra RESILIA (S3UR) transcatheter heart valve (THV) with cardiac computed tomography (CT) 30 days after implantation
- Participants
- 445 patients
- Outcome
- HALT on 4D CT
- Follow-up
- 30 days after TAVI
Methodological detailssubset of the OCEAN-TAVI registry, independent core laboratory
- Subset of the OCEAN-TAVI registry
- Independent core laboratory
Main finding
As reported in the abstract
HALT incidence
Hypoattenuating leaflet thickening (HALT) detected (of 445 patients)
95
21.3%
Observational data: associations, not effects.
Further findings
≤23 mm vs ≥26 mm
HALT incidence by THV size
P = 0.636
HALT >25% vs HALT ≤25%
Mean aortic gradient by HALT >25% vs ≤25% · 30 days
P = 0.007
HALT >50% vs HALT ≤50%
Mean aortic gradient by HALT >50% vs ≤50% · 30 days
P = 0.002
Independent predictors of HALT
- Hourglass-shaped THV frame
- P < 0.001
- Asymmetricity of THV leaflets
- P = 0.002
Original publication
Incidence, predictors, and clinical impact of hypoattenuating leaflet thickening following SAPIEN 3 Ultra RESILIA implantation. EuroIntervention. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →